-->

Tag: FDA accelerated approval 2023

Home / FDA accelerated approval 2023

Categories

The FDA has granted expedited approval to epcoritamab-bysp for the treatment of R/R follicular lymphoma

June 2024: The Food and Drug Administration has given accelerated approval to epcoritamab-bysp (Epkinly, Genmab US, Inc.), a bispecific CD20-directed CD3 T-cell engager, for adult patients with recurr...
fda-accelerated-approval-2023

Adagrasib with cetuximab has received accelerated approval by FDA for KRAS G12C-mutated colorectal cancer

  June 2024: The Food and Drug Administration has given accelerated approval to adagrasib (Krazati; Mirati Therapeutics, Inc.) in combination with cetuximab for adults who have KRAS G12C-mutat...
fda-accelerated-approval-2023

Scan the code